These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22634439)

  • 21. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Nov; 58(44):1241-5. PubMed ID: 19910912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009-2010 season.
    Weil-Olivier C; Lina B
    Vaccine; 2011 Sep; 29(40):7075-9. PubMed ID: 21777639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season.
    Bateman AC; Kieke BA; Irving SA; Meece JK; Shay DK; Belongia EA
    J Infect Dis; 2013 Apr; 207(8):1262-9. PubMed ID: 23341536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of influenza vaccine match and use rate to medically attended acute respiratory illnesses in older residents of Maryland. November 13, 2012.
    King JC; Lichenstein R; Magder LS
    Vaccine; 2013 Jan; 31(5):839-44. PubMed ID: 23219798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving history of influenza viruses and influenza vaccines.
    Hannoun C
    Expert Rev Vaccines; 2013 Sep; 12(9):1085-94. PubMed ID: 24024871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza guideline for South Africa--update 2008.
    Green RJ; Feldman C; Schoub B; Richards GA; Madhi SA; Zar HJ; Lalloo U; ; Klugman K; Phillips D; Cameron NA; Eggers RR
    S Afr Med J; 2008 Mar; 98(3 Pt 2):224-30. PubMed ID: 18652399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study.
    Mahmud S; Hammond G; Elliott L; Hilderman T; Kurbis C; Caetano P; Van Caeseele P; Kettner J; Dawood M
    Vaccine; 2011 Oct; 29(45):7975-81. PubMed ID: 21884747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influenza Virus: Dealing with a Drifting and Shifting Pathogen.
    Kim H; Webster RG; Webby RJ
    Viral Immunol; 2018 Mar; 31(2):174-183. PubMed ID: 29373086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urgent challenges in implementing live attenuated influenza vaccine.
    Singanayagam A; Zambon M; Lalvani A; Barclay W
    Lancet Infect Dis; 2018 Jan; 18(1):e25-e32. PubMed ID: 28780285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza.
    Cox NJ; Subbarao K
    Lancet; 1999 Oct; 354(9186):1277-82. PubMed ID: 10520648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: protective efficacy.
    Ochiai H; Shibata M; Kamimura K; Niwayama S
    Microbiol Immunol; 1986; 30(11):1151-65. PubMed ID: 3027513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza Vaccines: Successes and Continuing Challenges.
    Becker T; Elbahesh H; Reperant LA; Rimmelzwaan GF; Osterhaus ADME
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S405-S419. PubMed ID: 34590139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influenza vaccines: Past, present, and future.
    Kim YH; Hong KJ; Kim H; Nam JH
    Rev Med Virol; 2022 Jan; 32(1):e2243. PubMed ID: 33949021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current and emerging cell culture manufacturing technologies for influenza vaccines.
    Milián E; Kamen AA
    Biomed Res Int; 2015; 2015():504831. PubMed ID: 25815321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges of Making Effective Influenza Vaccines.
    Gouma S; Anderson EM; Hensley SE
    Annu Rev Virol; 2020 Sep; 7(1):495-512. PubMed ID: 32392457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).
    Feng L; Yang P; Zhang T; Yang J; Fu C; Qin Y; Zhang Y; Ma C; Liu Z; Wang Q; Zhao G; Yu H
    Hum Vaccin Immunother; 2015; 11(8):2077-101. PubMed ID: 26042462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.